Targeted therapy in advanced well-differentiated neuroendocrine tumors.
about
RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent mannerPharmacotherapy of Zollinger-Ellison syndrome.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesPancreatic neuroendocrine tumors: a comprehensive review.
P2860
Targeted therapy in advanced well-differentiated neuroendocrine tumors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Targeted therapy in advanced well-differentiated neuroendocrine tumors.
@ast
Targeted therapy in advanced well-differentiated neuroendocrine tumors.
@en
type
label
Targeted therapy in advanced well-differentiated neuroendocrine tumors.
@ast
Targeted therapy in advanced well-differentiated neuroendocrine tumors.
@en
prefLabel
Targeted therapy in advanced well-differentiated neuroendocrine tumors.
@ast
Targeted therapy in advanced well-differentiated neuroendocrine tumors.
@en
P2860
P1433
P1476
Targeted therapy in advanced well-differentiated neuroendocrine tumors.
@en
P2093
Chandrajit P Raut
Matthew H Kulke
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0313
P577
2011-02-23T00:00:00Z